RANBAXY

Sun Pharmaceutical Industries Limited has submitted to the Exchange vide letter dated March 30, 2015 a copy of disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Ranbaxy Laboratories Limited has informed that the ESOPs Allotment Committee of Directors at its meeting held on January 22, 2015, allotted 6,40,597 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 425,663,497 Equity Shares of Rs.5 each aggregating Rs. 2,128,317,485/-.

Ranbaxy Laboratories Limited has submitted to the Exchange vide letter dated October 22, 2014 a copy of disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors at its meeting held on October 11, 2014, alloted 5,59,561 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid- up Equity Share Capital of the Company post allotment is 424,572, 900 Equity Shares of Rs. 5 each aggregating Rs. 2,122,864,500/-.

Ranbaxy Laboratories Limited has submitted to the Exchange vide letter dated October 9, 2014 a copy of disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Ranbaxy Laboratories Limited has submitted to the Exchange vide letter dated September 2, 2014 a copy of disclosure pursuant to Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Ranbaxy Laboratories Limited has submitted to the Exchange vide letter dated July 24, 2014 a copy of disclosure pursuant to Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors at its meeting held on July 14, 2014 has allotted 207,529 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 424,013,339 Equity Shares of Rs.5 each aggregating Rs. 2,120,066,695/-.

Ranbaxy Laboratories Limited has submitted to the Exchange vide letter dated May 09, 2014 a copy of Disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Ranbaxy Laboratories Limited has submitted to the Exchange vide letter dated April 30, 2014 a copy of Disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Ranbaxy Laboratories Limited has submitted to the Exchange vide letter dated April 24, 2014 a copy of Disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on April 14, 2014, allotted 26,747 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 423,805,810 Equity Shares of Rs.5 each aggregating Rs. 2,119,029,050/-.

Ranbaxy Laboratories Limited has submitted to the Exchange vide letter dated January 16, 2014 a copy of Disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Ranbaxy Laboratories Limited has informed the Exchange that at the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on January 10, 2014, allotted 37,281 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 423,779,063 Equity Shares of Rs.5 each aggregating Rs. 2,118,895,315/-.

Life Insurance Corporation Limited has submitted to the Exchange vide letter dated December 23, 2013 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(3) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on October 11, 2013, allotted 12,273 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 423,141,782 Equity Shares of Rs.5 each aggregating Rs. 2,115,708,910/-.

Ranbaxy Laboratories Limited has submitted to the Exchange vide letter dated October 11, 2013 disclosure under Regulation 13(6) of the SEBI (Prohibition of Insider Trading) Regulations 1992.

Ranbaxy Laboratories Limited has submitted to the Exchange vide letter dated September 27, 2013 a copy of Disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Ranbaxy Laboratories Limited has submitted to the Exchange a copy of the disclosure under Regulation 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992

Ranbaxy Laboratories Limited has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on April 11,2011 allotted 110,922 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 421,363,230 Equity Shares of Rs. 5 each aggregating Rs. 2,106,816,150/-.

Ranbaxy Laboratories Ltd has informed the Exchange that Mr. Shivinder Mohan Singh, Director of the company has sold 303306 shares on April 4, 2006 of Ranbaxy Laboratories Ltd. The shareholding of Mr shivinder Mohan Singh after the said sale is 2120742 shares aggregating 0.57% of the total share capital of Ranbaxy Laboratories Ltd..

Ranbaxy Laboratories Ltd has informed the Exchange that (1) Mr Malvinder Mohan Singh has acquired 439032 shares on April 03, 2006 of Ranbaxy Laboratories Ltd. The shareholding of Mr Malvinder Mohan Singh after the said acquisition is 2877342 shares aggregating to 0.77% of the total share capital of Ranbaxy Laborities Ltd.. (2) Mr. Malvinder Mohan Singh, Chief Executive Officer and Managing Director of the company has sold 302908 shares on April 4, 2006 of Ranbaxy Laboratories Ltd. The shareholding of Mr Malvinder Mohan Singh after the said sale is 2574434 shares aggregating 0.69% of the total

Fidelity International has informed the Exchange that Funds under the management of FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries has sold 759,770 shares aggregating to 0.20% of the total paid up capital of Ranbaxy Laboratories Ltd on February 23, 2006. The mode of sale is Open market and the shareholding of Funds under the management of FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries after the said sale is 17,988,673 shares aggregating t

Ranbaxy Laboratories Ltd has informed the Exchange that Mr. V.K. Kaul, Director has sold 52,000 shares of Ranbaxy Laboratories Ltd on February 21, 2006. The mode of sale is Market sale and the shareholding of Mr. V.K. Kaul after the said sale is 200 shares of Ranbaxy Laboratories Ltd.

Ranbaxy Laboratories Ltd has informed the Exchange that Funds under the management of FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries has sold 759,770 shares aggregating to 0.20% of the share capital of Ranbaxy Laboratories Ltd on February 23, 2006. The mode of sale is market sale and the shareholding of Funds under the management of FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries after the said sale is 17,988,673 shares aggregating to 4.83

Ranbaxy Laboratories Ltd has informed the Exchange that the Funds under the management of FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries has acquired 258,626 shares aggregating to 0.07% of the total paid up capital of Ranbaxy Laboratories Ltd on February 01, 2006. The mode of acquisition is through Market purchase and the shareholding of Funds under the management of FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries after the said acquisitio

Fidelity International has informed the Exchange that Funds under the management of FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries has acquired 258,626 shares aggregating to 0.07% of the total paid up capital of Ranbaxy Laboratories Ltd on February 01, 2006. The mode of acquisition is Open market and the shareholding of Funds under the management of FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries after the said acquisition is 18,655,001 sh

Ranbaxy Laboratories Ltd has informed the Exchange regarding 22,70,652 shares held by Mr.Shivinder Mohan Singh, Director of the Company appointed on January 18, 2006.

Ranbaxy Laboratories Ltd has informed the Exchange that Mr. V.K. Kaul, director has sold 15,000 shares of Ranbaxy Laboratories Ltd on October 07, 2005. The mode of sale is Market sale and the shareholding of Mr. V.K. Kaul after the said sale is 52,200 shares aggregating to 0.014% of the share capital of Ranbaxy Laboratories Ltd..

Ranbaxy Laboratories Ltd has informed the Exchange that Mr. V.K. Kaul, director has sold 20,000 shares of Ranbaxy Laboratories Ltd on October 05, 2005. The mode of sale is Market sale and the shareholding of Mr. V.K. Kaul after the said sale is 67,200 shares aggregating to 0.018% of the share capital of Ranbaxy Laboratories Ltd.

Ranbaxy Laboratories Ltd has informed the Exchange that Mr. Ravi Mehrotra who was appointed as a Director of the Company on July 28, 2005, does not hold any shares of the Company.

Ranbaxy Laboratories Ltd has informed the Exchange regarding the sale and purchase of the shares by Ranbaxy Holding Company as follows: Ranbaxy Holding Company has (i) acquired 30,50,262 shares aggregating to 1.639% of the share capital of Ranbaxy Laboratories Ltd. by way of market purchases; (ii) acquired 6,94,444 shares aggregating to 0.373% of the share capital of Ranbaxy Laboratories Ltd. by way of pledge; and (iii) sold 134 shares of Ranbaxy Laboratories Ltd. The period of the said acquisition / sale is between March 04, 2005 to April 15, 2005 and the shareholding of Ranbaxy Holding Compa

Ranbaxy Laboratories Ltd has informed the Exchange that Mr. S.K.Patawari, Company Secretary of the Company, has acquired 608 shares of Ranbaxy Laboratories Ltd on April 12, 2005. The mode of acquisition is ESOP Allotment and the shareholding of Mr. S.K.Patawari after the said acquisition is 4798 shares of Ranbaxy Laboratories Ltd..

Ranbaxy Laboratories Ltd has informed the Exchange that Mr. V. K. Kaul, Director of the Company, has sold 10,400 shares of Ranbaxy Laboratories Ltd on March 24. 2005. The mode of sale is market sale and the shareholding of Mr. V. K. Kaul after the said sale is 43,600 shares aggregating to 0.02% of the share capital of Ranbaxy Laboratories Ltd.

Ranbaxy Laboratories Ltd has informed the Exchange that Ranbaxy Holding Company, which is under control of Mr. Malvinder Mohan Singh and Mr. Shivinder Mohan Singh, Promoters of Ranbaxy Laboratories Limited, have acquired 37,19,676 shares aggregating 2.00% of the total paid up capital of Ranbaxy Laboratories Ltd. during the period June 25, 2004 to March 04, 2005, and sold 6052 shares of Ranbaxy Laboratories Limited during the period August 17, 2004 to September 09, 2004. The mode of acquisition / sale is through the Open Market and the shareholding of Ranbaxy Holding Company after the said acqu

Ranbaxy Laboratories Ltd has informed the Exchange that Mr. S.K. Patawari, Company Secretary has been allotted 368 equity shares of the company on January 10, 2005 on exercise of stock options as per Employees Stock Option Scheme of the Company.

Ranbaxy Laboratories Ltd has informed the Exchange that Mr. S.K. Patawari, Company Secretary has been allotted 1125 equity shares of the company on October 11, 2004 on exercise of stock options as per Employees Stock Option Scheme of the Company.

Ranbaxy Laboratories Ltd has informed the Exchange that the ESOPs Allotment Committee of Directors at its meeting held on October 11, 2004 has allotted 59,602 Equity Shares on exercise of stock options under the Employees Stock Option Scheme of the Company. The paidup Equity Share Capital of the Company post allotment will be Rs.1858907420.